Nonalcoholic Fatty Liver Disease
McCarthy, E. (2014). Nonalcoholic fatty liver disease. Today's Dietitian. 16(1) 48. http://www.todaysdietitian.com/newarchives/010614p48.shtml
Nonalcoholic fatty liver disease is the most common liver disease in the United States. It is
characterized by the accumulation of triglycerides in in liver cells of people who do not abuse
alcohol. There are various levels of nonalcoholic fatty liver disease, ranging from fat accumulation
and inflammation, to cirrhosis and liver failure, to eventual kidney failure, heart failure, and death.
A majority of obese people in the United States (80-90% estimated) also have NAFLD and
36% of these have an aggressive form of NAFLD. A high BMI does not necessarily mean fatty liver
disease. There have been more and more cases recently with NAFLD patients who have a normal
BMI, but do have central adiposity and insulin resistance. This suggests a direct correlation between
hepatic fat content and visceral adiposity. Diet has a lot to do with this. High total fat intake, high
saturated fat intake, high trans fatty intake, and high processed carbohydrate have all been associated
with an increased risk of NAFLD.
No specific medications have been approved to treat NAFLD. The current standard of care
focuses on lifestyle interventions such as diet and exercise. Sustained weight loss has been the most
effective treatment of NAFLD and should be the main goal of any treatment plan. A weight loss as
little as 5-10% has shown significant improvement in inflammation. It is important to monitor dietary
intake and physical activity of the patient, but also educate their family members to ensure a good
support system and a higher rate of success.
-DU
Nonalcoholic fatty liver disease is the most common liver disease in the United States. It is
characterized by the accumulation of triglycerides in in liver cells of people who do not abuse
alcohol. There are various levels of nonalcoholic fatty liver disease, ranging from fat accumulation
and inflammation, to cirrhosis and liver failure, to eventual kidney failure, heart failure, and death.
A majority of obese people in the United States (80-90% estimated) also have NAFLD and
36% of these have an aggressive form of NAFLD. A high BMI does not necessarily mean fatty liver
disease. There have been more and more cases recently with NAFLD patients who have a normal
BMI, but do have central adiposity and insulin resistance. This suggests a direct correlation between
hepatic fat content and visceral adiposity. Diet has a lot to do with this. High total fat intake, high
saturated fat intake, high trans fatty intake, and high processed carbohydrate have all been associated
with an increased risk of NAFLD.
No specific medications have been approved to treat NAFLD. The current standard of care
focuses on lifestyle interventions such as diet and exercise. Sustained weight loss has been the most
effective treatment of NAFLD and should be the main goal of any treatment plan. A weight loss as
little as 5-10% has shown significant improvement in inflammation. It is important to monitor dietary
intake and physical activity of the patient, but also educate their family members to ensure a good
support system and a higher rate of success.
-DU
Research participants needed for a pharmaceutical research study to test an investigational drug for obesity. We are looking for overweight males and females eighteen years or older including those who may have type ii diabetes or have been told that they have fatty liver. Participants must be available for ten outpatient clinic visits over a period of approximately 5 months.
ReplyDeleteEnrolled participants will be compensated for time and participation.
For more information call seaview research at three zero five, six four six, six seven eight five https://studyscavengerapp.com/quotient-sciences-paid-clinical-trial-investigate-efficacy-lik066-obese-patients-volunteers-non-alcoholic-steatohepatitis-fatty-liver-disease-miami-fl/
#miami #broward #nafld